Perfil de utilización de los anti-factor de necrosis tumoral en pacientes de Colombia

Perfil de utilización de los anti-factor de necrosis tumoral en pacientes de Colombia

Introducción. Los inhibidores del factor de necrosis tumoral alfa han presentado un consumo creciente y generan una importante carga económica para los sistemas de salud. Objetivo. Determinar los patrones de prescripción de inhibidores del factor de necrosis tumoral en una población de personas afil...

Full description

Bibliographic Details
Main Authors:	Jorge Machado, Juan Carlos Moncada, Ricardo Pineda
Format:	Article
Language:	English
Published:	Instituto Nacional de Salud 2011-03-01
Series:	Biomédica: revista del Instituto Nacional de Salud
Subjects:	Antirheumatic agents tumor necrosis factor-alpha arthritis, rheumatoid arthritis, juvenile rheumatoid spondylitis, ankylosing psoriatic, Colombia
Online Access:	http://www.revistabiomedica.org/index.php/biomedica/article/view/319

Similar Items

Gait characteristics associated with the foot and ankle in inflammatory arthritis: a systematic review and meta‐analysis
by: Matthew Carroll, et al.
Published: (2015-01-01)

Persistence and costs with subcutaneous TNF-alpha inhibitors in immune-mediated rheumatic disease stratified by treatment line
by: Svedbom A, et al.
Published: (2017-01-01)

Impact of tumor necrosis factor inhibitors and methotrexate on diabetes mellitus among patients with inflammatory arthritis
by: Santhi Mantravadi, et al.
Published: (2020-09-01)

Comorbidities in inflammatory joint and spine diseases in XXI century
by: I Z Gaydukova, et al.
Published: (2018-12-01)

Biologics and cardiovascular events in inflammatory arthritis: a prospective national cohort study
by: Joshua L. Lee, et al.
Published: (2018-08-01)

Persistence to subcutaneous biological agents in Hungarian patients treated for inflammatory arthritis
by: Takacs P, et al.
Published: (2019-01-01)

Association between use of disease-modifying antirheumatic drugs and diabetes in patients with ankylosing spondylitis, rheumatoid arthritis, or psoriasis/psoriatic arthritis: a nationwide, population-based cohort study of 84,989 patients
by: Chen HH, et al.
Published: (2017-05-01)

Evaluation of the safety and satisfaction of rheumatic patients with accelerated infliximab infusion
by: Jozélio Freire de Carvalho, et al.
Published: (2018-08-01)

Rheumatoid arthritis and spondyloarthritis prevalence in four European countries - a comparative study
by: Zlatković-Švenda Mirjana, et al.
Published: (2022-01-01)

Significance of Interleukin (IL)-4 and IL-13 in Inflammatory Arthritis
by: Milena Iwaszko, et al.
Published: (2021-11-01)

Circulating miRNA Correlates with Lipid Profile and Disease Activity in Psoriatic Arthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis Patients
by: Krzysztof Bonek, et al.
Published: (2022-04-01)

Disease Differentiation and Monitoring of Anti-TNF Treatment in Rheumatoid Arthritis and Spondyloarthropathies
by: Katarzyna Bogunia-Kubik, et al.
Published: (2021-07-01)

The data project: a shared approach between stakeholders of the healthcare system in definition of a therapeutic algorithm for inflammatory arthritis
by: I. Pantano, et al.
Published: (2023-03-01)

Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?
by: M. Rossini, et al.
Published: (2015-03-01)

Use of antidepressants and benzodiazepine-related hypnotics before and after initiation of TNF-α inhibitors or non-biological systemic treatment in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis
by: Philip Brenner, et al.
Published: (2020-02-01)

Real-Life Retention Rates and Reasons for Switching of Biological DMARDs in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
by: Vandana Bhushan, et al.
Published: (2021-09-01)

Nod-like receptors in inflammatory arthritis
by: Sahib Singh Madahar, et al.
Published: (2024-02-01)

Inflammatory arthritis and eye diseases: a Mendelian randomization study
by: Xinlin Nie, et al.
Published: (2023-10-01)

Effect of Dysmetabolisms and Comorbidities on the Efficacy and Safety of Biological Therapy in Chronic Inflammatory Joint Diseases
by: Laura Cometi, et al.
Published: (2020-05-01)

Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis
by: M. Elaine Husni, et al.
Published: (2022-03-01)

A Prospective Study to Evaluate the Impact of Golimumab Therapy on Work Productivity and Activity, and Quality of Life in Patients With Rheumatoid Arthritis, Psoriasis Arthritis and Axial Spondyloarthritis in a Real Life Setting in AUSTRIA. The GO-ACTIVE Study
by: Christian Dejaco, et al.
Published: (2022-06-01)

The use of biological disease-modifying antirheumatic drugs for inflammatory arthritis in Korea: results of a Korean Expert Consensus
by: Eun-Jung Park, et al.
Published: (2020-01-01)

Newly diagnosed seropositive rheumatoid arthritis in a 52-year-old man superimposed on long-standing ankylosing spondylitis during secukinumab treatment
by: Jaroslaw Nowakowski, et al.
Published: (2023-10-01)

Coexistence of rheumatoid arthritis and ankylosing spondylitis
by: Tacjana Anna Barczyńska, et al.
Published: (2015-12-01)

Body Mass Index and Disease Activity in Chronic Inflammatory Rheumatic Diseases: Results of the Cardiovascular in Rheumatology (Carma) Project
by: Jesús A. Valero-Jaimes, et al.
Published: (2021-01-01)

Imaging of juvenile spondyloarthritis. Part I: Classifications and radiographs
by: Iwona Sudoł-Szopińska, et al.
Published: (2017-09-01)

Classifications and imaging of juvenile spondyloarthritis
by: Iwona Sudoł-Szopińska, et al.
Published: (2018-09-01)

TEMPOROMANDIBULAR JOINT INVOLVEMENT IN RHEUMATOID ARTHRITIS AND ANKYLOSING SPONDYLITIS: A CROSS-SECTIONAL STUDY
by: Cristina Iordache, et al.
Published: (2018-01-01)

Tumor Necrosis Factor Alpha -308G/A Gene Polymorphisms Combined with Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratio Predicts the Efficacy and Safety of Anti-TNF-α Therapy in Patients with Ankylosing Spondylitis, Rheumatoid Arthritis, and Psoriasis Arthritis
by: Ziran Wang, et al.
Published: (2022-01-01)

Ankylosing spondylitis and psoriatic arthritis: clinical and economic consequences of the use of etanercept
by: Viola Sacchi, et al.
Published: (2010-06-01)

The impact of SARS-CoV-2 infection and vaccination on inflammatory arthritis: a cohort study
by: Giovanni Striani, et al.
Published: (2023-07-01)

Risk of Autoimmune Diseases Following Optic Neuritis: A Nationwide Population-Based Cohort Study
by: Kevin Sheng-Kai Ma, et al.
Published: (2022-06-01)

Efficacy and safety of total glucosides of paeony in the treatment of 5 types of inflammatory arthritis: A systematic review and meta-analysis
by: Kailin Yang, et al.
Published: (2023-09-01)

Six-Month Follow-Up of Periodontal Condition in Rheumatoid Arthritis and Ankylosing Spondylitis Arthritis Patients Undergoing Anti-Tumour Necrosis Factor-α Therapy
by: Ildikó Tar, et al.
Published: (2024-01-01)

Intestinal microsporidiosis: a hidden risk in rheumatic disease patients undergoing anti-tumor necrosis factor therapy combined with disease-modifying anti-rheumatic drugs?
by: Nadia Emi Aikawa, et al.
Published: (2011-01-01)

A comparative study of total knee arthroplasty outcome for stiff knee with or without sequential antirheumatic drug treatment
by: Cheng-Qi Jia, et al.
Published: (2021-08-01)

Efficacy and Safety of Curcumin and Curcuma longa Extract in the Treatment of Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trial
by: Liuting Zeng, et al.
Published: (2022-07-01)

The Role of Sclerostin in Rheumatic Diseases: A Review
by: Łukasz Jaśkiewicz, et al.
Published: (2023-09-01)

NEW POSSIBILITIES OF PHARMACOTHERAPY FOR IMMUNOINFLAMMATORY RHEUMATIC DISEASES: A FOCUS ON INHIBITORS OF INTERLEUKIN-17
by: E. L. Nasonov
Published: (2017-03-01)

IL-23/IL-17 INHIBITORS IN IMMUNOINFLAMMATORY RHEUMATIC DISEASES: NEW HORIZONS
by: E. L. Nasonov, et al.
Published: (2019-09-01)